Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To detect signals of adverse drug events after imipenem treatment using the Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database (KIDS-KD). Materials and Methods: We performed data mining using KIDS-KD, which was constructed using spontaneously reported adverseevent (AE) reports between December 1988 and June 2014. We detected signals calculated the proportional reporting ratio, reporting odds ratio, and information component of imipenem. We defined a signal as any AE that satisfied all three indices. The signals were compared with drug labels of nine countries. Results: There were 807582 spontaneous AEs reports in the KIDS-KD. Among those, the number of antibiotics related AEs was 192510; 3382 reports were associated with imipenem. The most common imipenem-associated AE was the drug eruption; 353 times. We calculated the signal by comparing with all other antibiotics and drugs; 58 and 53 signals satisfied the three methods. We compared the drug labelling information of nine countries, including the USA, the UK, Japan, Italy, Switzerland, Germany, France, Canada, and South Korea, and discovered that the following signals were currently not included in drug labels: hypokalemia,cardiac arrest, cardiac failure, Parkinson’s syndrome, myocardial infarction, and prostate enlargement. Hypokalemia was an additional signal compared with all other antibiotics, and the other signals were not different compared with all other antibiotics and all other drugs. Conclusion: We detected new signals that were not listed on the drug labels of nine countries. However, further pharmacoepidemiologicresearch is needed to evaluate the causality of these signals.
Abstract
Purpose: To detect signals of adverse drug events after imipenem treatment using the Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database (KIDS-KD). Materials and Methods: We performed data mining using KIDS-KD, which was constructed using spontaneously reported adverseevent (AE) reports between December 1988 and June 2014. We detected signals calculated the proportional reporting ratio, reporting odds ratio, and information component of imipenem. We defined a signal as any AE that satisfied all three indices. The signals were compared with drug labels of nine countries. Results: There were 807582 spontaneous AEs reports in the KIDS-KD. Among those, the number of antibiotics related AEs was 192510; 3382 reports were associated with imipenem. The most common imipenem-associated AE was the drug eruption; 353 times. We calculated the signal by comparing with all other antibiotics and drugs; 58 and 53 signals satisfied the three methods. We compared the drug labelling information of nine countries, including the USA, the UK, Japan, Italy, Switzerland, Germany, France, Canada, and South Korea, and discovered that the following signals were currently not included in drug labels: hypokalemia,cardiac arrest, cardiac failure, Parkinson’s syndrome, myocardial infarction, and prostate enlargement. Hypokalemia was an additional signal compared with all other antibiotics, and the other signals were not different compared with all other antibiotics and all other drugs. Conclusion: We detected new signals that were not listed on the drug labels of nine countries. However, further pharmacoepidemiologicresearch is needed to evaluate the causality of these signals.
참고문헌 (32)
- "What is a signal?" (2013)[URL]
- Trifirò G, "Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?", Pharmacoepidemiol Drug Saf, 18, pp.1176~1184 (2009)
- van Puijenbroek E, "Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions", Drug Saf, 26, pp.293~301 (2003)
- Egberts AC, "Use of measures of disproportionality in pharmacovigilance: three Dutch examples", Drug Saf, 25, pp.453~458 (2002)
- Hornik CP, "Adverse events associated with meropenem versus imipenem", cilastatin therapy in a large retrospective cohort of hospitalized infants, 2013, pp.32, 748~753
- "Label: imipenem and cilastatin- imipenem and cilastatin sodium injection, powder, for solution" (2012)[URL]
- "Imipenem-precautions" (2013)[URL]
- "User guide:Korea Institute of Drug Safety and Risk Management-Korea adverse event reporting system database (KIDS-KD)" (2014)[URL]
- Ye X, "A computerized system for signal detection in spontaneous reporting system of Shanghai China", Pharmacoepidemiol Drug Saf, 18, pp.154~158 (2009)
- Wilson AM, "Application of data mining techniques in pharmacovigilance", Br J Clin Pharmacol, 57, pp.127~134 (2004)
- Seong JM, "Signal detection of sildenafil in Korean spontaneous adverse event reports", J Pharmacoepidemiol Risk Manag, 2, pp.38~44 (2009)
- Gould AL, "Practical pharmacovigilance analysis strategies", Pharmacoepidemiol Drug Saf, 12, pp.559~574 (2003)
- Bate A, "Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs", Eur J Clin Pharmacol, 58, pp.483~490 (2002)
- Li C, "A web-based quantitative signal detection system on adverse drug reaction in China", Eur J Clin Pharmacol, 65, pp.729~741 (2009)
- Bate A, "Quantitative signal detection using spontaneous ADR reporting", Pharmacoepidemiol Drug Saf, 18, pp.427~436 (2009)
- Grundmark B, "Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area", Eur J Clin Pharmacol, 70, pp.627~635 (2014)
- Cannon JP, "The risk of seizures among the carbapenems: a meta-analysis", J Antimicrob Chemother, 69, pp.2043~2055 (2014)
- Chen Z, "Efficacy and safety of tigecycline monotherapy vs. imipenem", cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial, 2010, pp.10, 217~
- Drusano GL, "Safety and tolerability of multiple doses of imipenem", cilastatin, 1985, pp.37, 539~543
- Babinchak T, "The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data", Clin Infect Dis, 41(Suppl 5), pp.S354~S367 (2005)
- Torres A, "Treatment of severe nosocomial pneumonia:a prospective randomised comparison of intravenous ciprofloxacin with imipenem", cilastatin, 2000, pp.55, 1033~1039
- Ramasamy R, "The prospect of serum magnesium and an electrolyte panel as an adjuvant cardiac biomarker in the management of acute myocardial infarction", J Clin Diagn Res, 7, pp.817~820 (2013)
- Bardai A, "Epilepsy is a risk factor for sudden cardiac arrest in the general population", PLoS One, 7, pp.e42749~ (2012)
- Lindquist M, "A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database", Drug Saf, 23, pp.533~542 (2000)
- Bandekar MS, "Quality check of spontaneous adverse drug reaction reporting forms of different countries", Pharmacoepidemiol Drug Saf, 19, pp.1181~1185 (2010)
- Finkelsztejn A, "Imipenem-associated encephalopathy: alert to physicians", Arq Neuropsiquiatr, 68, pp.137~139 (2010)
- "The State of the World’s Antibiotics" (2015)[URL]
- Papp-Wallace KM, "Carbapenems:past, present, and future", Antimicrob Agents Chemother, 55, pp.4943~4960 (2011)
- van Puijenbroek EP, "Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole", Br J Clin Pharmacol, 47, pp.689~693 (1999)
- Lindquist M, "From association to alert--a revised approach to international signal analysis", Pharmacoepidemiol Drug Saf, 8(Suppl 1), pp.S15~S25 (1999)
- "WHOART:Structure"[URL]
- Alecu I, "Mapping of the WHOART terminology on Snomed CT to improve grouping of related adverse drug reactions", Stud Health Technol Inform, 124, pp.833~838 (2006)